Next-Generation Circulating Tumor Cell Test Demonstrates High Efficiency and Accuracy in New Study
04/04/2013 06:28 (23:34 minutes ago)
|
The FINANCIAL -- Veridex, LLC announced that the first study of the company’s next-generation circulating tumor cell technology, developed in collaboration with researchers at Massachusetts General Hospital, has been published in Science Translational Medicine.
.............................
The new technology tests for CTCs from the blood of cancer patients using advanced microfluidic separation techniques integrated with innovative magnetic sorting to isolate a broad spectrum of rare circulating cancer cells. This technology will allow physicians to get information about a patient’s cancer at the time treatment is being administered, one of the key components to enabling personalized medicine.
|
No comments:
Post a Comment